Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy

BACKGROUND: A high hepatitis B virus (HBV) load is a common exclusion criterion in hepatocellular carcinoma (HCC) clinical trials for anti-programmed cell death (PD)-1 immunotherapy. However, the validity of this criterion is barely verified. This study aimed to evaluate the impact of baseline HBV D...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xuqi, Hu, Dandan, Yang, Zhoutian, Liu, Zheng, Wang, Juncheng, Chen, Jinbin, Xu, Li, Zhou, Zhongguo, Chen, Minshan, Zhang, Yaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718972/
https://www.ncbi.nlm.nih.gov/pubmed/33294424
http://dx.doi.org/10.2147/JHC.S278527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718972/
https://www.ncbi.nlm.nih.gov/pubmed/33294424
http://dx.doi.org/10.2147/JHC.S278527

Ejemplares similares